Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

ACTIV-3/ TICO (sotrovimab)
 
NCT04501978
RCTsotrovimab (Xevudy; VIR-7831)placeboCOVID 19 hospitalizedlow
184/183 inconclusive
  • inconclusive 12 % increase in recovery (PE) with a high degree of certainty due to low risk of bias
Prematurely discontinued for futility after enrollment of 300 patients.

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).